Magee Thomson Investment Partners’s Tvardi Therapeutics TVRD Stock Holding History

Magee Thomson Investment Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Sell	1 -2	-67%	-$1.07K	﹤0.01%	69
2016 Q4	$1K	Sell	3 -1	-25%	-$321	﹤0.01%	72
2016 Q3	$1K	Buy	4 +2	+100%	+$433	﹤0.01%	72
2016 Q2	$0	Sell	2 -6	-75%	-$1.31K	﹤0.01%	108
2016 Q1	$1K	Hold	8	–	–	﹤0.01%	98
2015 Q4	$5K	Buy	8 +2	+33%	+$1.1K	﹤0.01%	56
2015 Q3	$4K	Sell	6 -11	-65%	-$7.36K	﹤0.01%	81
2015 Q2	$8K	Buy	+17	New	+$6.57K	﹤0.01%	36

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Magee Thomson Investment Partners's TVRD Position: Q1 2017 in Review

Magee Thomson Investment Partners reduced its Tvardi Therapeutics (TVRD) stake by 67% in Q1 2017, selling an estimated $1.07K and leaving 1 share worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #69.

Magee Thomson Investment Partners first reported a position in TVRD in Q2 2015 and has held it in 8 quarters since. The position peaked at $8K in Q2 2015. 114 funds tracked by Wall St. Rank hold TVRD as of Q1 2017.

Magee Thomson Investment Partners held 1 share of Tvardi Therapeutics worth $1K as of Q1 2017.
Magee Thomson Investment Partners sold 2 Tvardi Therapeutics shares in Q1 2017, an estimated $1.07K.
Tvardi Therapeutics made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #69 holding.
Magee Thomson Investment Partners first reported a position in Tvardi Therapeutics in Q2 2015 and has held it in 8 quarters since.
Magee Thomson Investment Partners's Tvardi Therapeutics position peaked at $8K in Q2 2015.
114 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.